Susquehanna International Group LLP lifted its position in shares of Artivion, Inc. (NYSE:AORT – Free Report) by 584.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,531 shares of the company’s stock after acquiring an additional 87,544 shares during the period. Susquehanna International Group LLP owned about 0.21% of Artivion worth $2,304,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Royal Bank of Canada boosted its stake in Artivion by 73.1% in the first quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock valued at $3,430,000 after acquiring an additional 39,553 shares during the period. Orbimed Advisors LLC bought a new stake in shares of Artivion in the 1st quarter worth approximately $5,530,000. Vanguard Group Inc. boosted its position in Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after purchasing an additional 141,030 shares during the period. Summit Creek Advisors LLC bought a new position in Artivion during the 2nd quarter worth $2,704,000. Finally, Fifth Third Bancorp increased its position in Artivion by 58,029.7% in the first quarter. Fifth Third Bancorp now owns 123,235 shares of the company’s stock worth $4,513,000 after buying an additional 123,023 shares during the period. 86.37% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Stifel Nicolaus set a $45.00 target price on Artivion in a research note on Monday, June 1st. Finally, Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Artivion currently has an average rating of “Moderate Buy” and a consensus target price of $44.83.
Artivion Price Performance
Shares of AORT stock opened at $26.77 on Monday. The stock’s 50 day simple moving average is $25.64 and its 200 day simple moving average is $29.60. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -382.37 and a beta of 1.24.
Artivion (NYSE:AORT – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The firm had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. As a group, research analysts predict that Artivion, Inc. will post 0.45 EPS for the current year.
Insider Transactions at Artivion
In related news, SVP Andrew M. Green sold 44,001 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 114,978 shares of company stock worth $2,965,155. Insiders own 6.30% of the company’s stock.
Artivion Profile
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Read More
- Five stocks we like better than Artivion
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
